Pyruvate kinase M2

Pyruvate kinase M2
Name	Pyruvate kinase M2
Ec number	2.7.1.40
Gene	PKM
Organism	Homo sapiens
Location	cytosol, nucleus

Pyruvate kinase M2 is a splice isoform of the human pyruvate kinase encoded by the PKM gene, acting as a key glycolytic enzyme and metabolic regulator in proliferating mammalian cells. Discovered in contexts including Embryonic development and Cancer research, it integrates signals from pathways such as PI3K/AKT pathway, mTOR, and HIF-1α to modulate flux through glycolysis, anabolic processes, and gene expression.

Structure and Isoforms

Pyruvate kinase M2 exists as monomers, dimers, and tetramers with quaternary assembly influencing activity, a feature characterized using methods from X-ray crystallography and cryo-electron microscopy by groups at institutions like Harvard University and Max Planck Society and reported in journals associated with Nature and Science. The PKM gene yields M1 and M2 isoforms through alternative splicing regulated by factors such as hnRNP A1, hnRNP A2/B1, and PTB; these splicing regulators were studied in labs at Cold Spring Harbor Laboratory and MIT. Structural domains include the A, B, and C domains common to pyruvate kinases described in comparative studies involving Escherichia coli, Saccharomyces cerevisiae, and Mus musculus orthologs. Crystal structures reveal allosteric binding sites for fructose-1,6-bisphosphate and other effectors, with insights contributed by researchers affiliated with UCSF and University of Cambridge.

Regulation and Post-translational Modifications

Regulatory control of M2 involves allosteric effectors such as fructose-1,6-bisphosphate and post-translational modifications mapped by proteomics centers at Broad Institute and European Bioinformatics Institute. Phosphorylation by kinases including ERK1/2 and Src alters oligomeric state and localization; ubiquitination and SUMOylation pathways studied at EMBL and Johns Hopkins University further modulate stability. Acetylation by acetyltransferases associated with CBP/p300 and deacetylation by SIRT1 influence enzyme activity and were reported in collaborations with Stanford University researchers. Oxidation and nitrosylation under conditions studied by groups at NIH and Max Delbrück Center modify catalytic cysteines, tying redox signaling from NADPH oxidase and mitochondrial reactive oxygen species pathways to PKM2 function.

Catalytic Mechanism and Kinetics

The enzyme catalyzes transfer of a phosphate from phosphoenolpyruvate to ADP to form ATP and pyruvate, a mechanism elucidated using kinetics approaches developed at University of Oxford and University of California, Berkeley. Michaelis–Menten parameters vary by oligomeric state and cellular context; tetramers exhibit high affinity and Vmax, while dimers show lower catalytic efficiency, a phenomenon characterized in studies published by teams at University of Tokyo and ETH Zurich. Transition state stabilization involves conserved residues analogous to those identified in studies of Lactococcus lactis pyruvate kinase and was probed using site-directed mutagenesis in labs at Yale University and University of Chicago.

Role in Cellular Metabolism and Glycolysis

PKM2 regulates metabolic flux between ATP production and biosynthetic precursor generation, affecting pathways connected to Pentose phosphate pathway, Serine biosynthesis pathway, and One-carbon metabolism investigated at centers including The Francis Crick Institute and Institut Pasteur. In rapidly dividing cells studied in contexts such as Tumor microenvironment research at Dana-Farber Cancer Institute and MD Anderson Cancer Center, PKM2-mediated control of pyruvate fate influences mitochondrial oxidation, lactate production, and anabolic intermediates. Interactions with signaling hubs like Ras, c-Myc, and TP53 connect metabolic control to proliferation programs characterized in work from Salk Institute and Cold Spring Harbor Laboratory.

Non-metabolic Functions and Nuclear Activity

Beyond catalysis, PKM2 translocates to the nucleus where it functions as a coactivator and protein kinase, phosphorylating substrates including histone H3 and modulating transcription factors such as HIF-1α, β-catenin, and STAT3—findings reported by investigators at Imperial College London and University College London. Nuclear PKM2 participates in chromatin remodeling and gene expression programs linked to Cell cycle regulation and Apoptosis pathways, with mechanistic work contributed by teams at Columbia University and University of Pennsylvania. Nuclear functions tie metabolic state to epigenetic control similar to mechanisms explored in studies of p300, HDACs, and BRD4.

Clinical Significance and Disease Associations

Altered PKM2 expression and activity are implicated in cancer, metabolic disorders, and immune cell activation; its role in the Warburg effect has been a focus of translational research at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Research Center. PKM2 splice regulation and isoform switching are relevant to prognosis in malignancies such as glioblastoma, colorectal cancer, and hepatocellular carcinoma, with clinical correlations described in multicenter studies involving Mayo Clinic and Cleveland Clinic. Associations with inflammatory diseases were investigated by consortia including Wellcome Trust–funded groups and the European Union collaborations. Germline and somatic mutations in PKM-related pathways intersect with syndromes elucidated by teams at Genomics England and Human Genome Project participants.

Therapeutic Targeting and Inhibitors

PKM2 is a target for small molecules that stabilize tetrameric active forms or inhibit non-canonical functions; compound discovery programs have been run at pharmaceutical companies such as Pfizer, Novartis, and Roche and reported in partnerships with academic labs at University of North Carolina at Chapel Hill and University of Toronto. Examples include activators that mimic fructose-1,6-bisphosphate and inhibitors that block nuclear translocation; preclinical studies were conducted in collaboration with NCI and biotech firms emerging from Stanford University spinouts. Clinical development faces challenges similar to those encountered in targeted therapies for EGFR, BRAF, and ALK due to context-dependent effects on metabolism and signaling; strategies integrating PKM2 modulation with immunotherapies from NIH–funded trials are under investigation.

Category:Enzymes